Search PubMed⌕ Search

Biomedical subjects

M Shinomiya

Publications and source records attributed to M Shinomiya.

At least 73 records · Page 4Linked to original sources

A familial hyperalphalipoproteinemia with low uptake of high density lipoproteins into peripheral lymphocytes.

A patient with an extremely high level of high density lipoprotein (HDL)-cholesterol and HDLc-like particles in the serum is discussed. The patient was a 46-year-old female with a serum total cholesterol concentration of 382 mg/dl and HDL-cholesterol level of 214 mg/dl. The HDL-cholesterol levels of her mother, brother, sister and 2 of her daughters were 82 mg/dl, 82 mg/dl, 74 mg/dl, 82 mg/dl and 82 mg/dl, respectively (mean HDL-cholesterol levels of control subjects: 52 +/- 6 mg/dl in males and 55 +/- 8 mg/dl in females). Her serum apolipoprotein A-I and E levels were elevated. Zonal ultracentrifugal analysis of her serum lipoproteins showed that the increased level of HDL-cholesterol was mainly due to HDL2; HDLc-like particles were also recognized between the LDL and HDL fractions. The incorporation of the patient's HDL and HDLc-like particles into cultured HepG2 cells was almost the same as that of HDL (1.063 less than d less than 1.21) from normal control serum. The incorporation of normal control HDL into the patient's peripheral blood lymphocytes was markedly less than that into lymphocytes from normal controls. These findings are discussed in terms of the reason for hyperalphalipoproteinemia in this patient.

Animals↗

[Peri- and postnatal study of cefodizime sodium in mice--intravenous administration from late gestation through period of lactation].

Peri- and postnatal study of cefodizime sodium (THR-221), a new developed cephem-type antibiotics, was carried out with ICR mice. THR-221 at dose levels of 0, 300, 1000 and 3000 mg/kg/day were administered intravenously to pregnant and delivered dams from day 15 of gestation through day 21 of lactation. No changes in body weights of dams in all treated groups but slight decrease in food consumptions of 3000 mg/kg/day group were observed. Treated sites, tails of a few dams in this group, were affected with inflammatory lesions because of repeated dosing. Neonates from dams treated with 3000 mg/kg/day were slightly decreased in body weight at birth. At term sacrifice of F 1 of 10 weeks age, absolute and relative spleen weights were decreased in male 3000 mg/kg/day group and in female 1000 and 3000 mg/kg/day group. No effects on other physical, behavioral or reproductive ability examinations of F 1 offspring were showed. It is suggested that no effect dose level of THR-221 is 1000 mg/kg/day and that of F 1 offspring is 300 mg/kg/day.

Animals↗

[Local irritation studies of cefodizime sodium].

Four local irritation studies of cefodizime sodium (THR-221), a new developed cephem-type antibiotics, were carried out with NZW rabbits. 1. In eye irritation test, 25% THR-221 water solution had no irritancy on eye mucosa in rabbits. 2. In single injective intramuscular irritation study, regardless of solvents (water or 0.5% lidocaine), 25% THR-221 solution had irritancy equal to 0.75% acetic acid. But recovery process of the muscle injured with THR-221 was faster and better than with 0.75% acetic acid. 3. In five days injective muscular irritation study, the irritancy of 25% THR-221 water solution on the muscle was milder than that of CTT or CET. Histopathological damage with THR-221, necrosis/degeneration of muscle fibers and edema/hemorrhage in interstitium etc., were well recovered. 4. In vessel irritation study, 10% or more THR-221 water solution had irritancy on ear vessel. THR-221, as same as CTT, caused organized thrombi and inflammation at the surrounding area. The degree of irritation of 20% THR-221 solution was slightly stronger than that of 20% CET, but weaker than that of 20% CTT. 5. In a clinical phase, it is to be desired that THR-221 like as CTT or CET shall be avoided repeated intramuscular or intravenous injections at the same site.

Animals↗

Long term result of LDL selective plasma adsorption therapy on familial hypercholesterolemia.

A newly developed low density lipoprotein (LDL) selective adsorption column from the separated plasma was applied to one patient of heterozygous familial hypercholesterolemia for 20 months at intervals of two weeks. LDL selective adsorption column, Liposorber LA-40, contains 400 ml of swollen dextran sulfate cellulose beads. The long-term, 20 month results of treatment with LDL selective plasma adsorption therapy are reported. LDL selective plasma adsorption therapy by Liposorber is useful in decreasing LDL-cholesterol of familial hypercholesterolemia and is more specific and produces a smaller loss of useful components of the serum than the double filtration plasmapheresis treatment. This treatment is effective in improving clinical conditions of familial hypercholesterolemia. In spite of our lengthy treatment with this therapy, no blood transfusion and no replacement of fluids was done in 20 months.

Blood Proteins↗

Effect of pirozadil on lipids, lipoproteins and apolipoproteins in Japanese with type IIa hyperlipoproteinemia.

Pirozadil (pyridine 2,6-dimethanol-bis(3,4,5-trimethoxybenzoate), Pemix) was administered for 16 weeks at a dose of 1.5 or 2.0 g/d to 15 adults with Type IIa hyperlipidemia. All patients had achieved a stable weight and were given a diet before treatment. Plasma lipids, lipoproteins and apolipoproteins were measured at 4-week intervals. Pirozadil reduced the mean total cholesterol (TC) level from 291.0 mg/dl to 260.8 mg/dl in 16 weeks (p less than 0.05). The mean percentage decrease was 8.5% in week 16. Low density lipoprotein (LDL)-cholesterol and apolipoprotein B (apoB) decreased 9.7% and 8.5%, respectively, in week 16. A decrease of more than 10% in TC, representing a decrease of more than 30 mg/dl, was observed in 12 of the 15 patients. These 12 patients, who were regarded as responders, showed mean decreases in the levels of TC, LDL-cholesterol and apoB of 13.7%, 10.4% and 11.7%, respectively, but no significant change in the level of high density lipoprotein (HDL)-cholesterol or serum triglycerides. Eight of 11 patients in the lower dose group (1.5 g/d) and all 4 patients who had obtained the higher dose (2.0 g/d) were responders. Suspected side effects of pirozadil were edema, numbness of the extremities and palpitation. The results obtained suggest the beneficial effect of pirozadil on serum lipids in patients with Type IIa hyperlipoproteinemia.

Apolipoproteins↗

[Acute toxicity test on dermal application of NT-1 tape and 10% nitroglycerin (NT-1 ointment)].

An acute toxicity of NT-1 tape was investigated in mice, rats and rabbits, and also an acute toxicity of NT-1 ointment in rabbits. An irritation of NT-1 tape was investigated in rabbits. Dead animals treated with NT-1 tape or ointment were not observed in reliable maximum administration dose of 0.88 mg/body as GTN (nitroglycerin) in mice (male; about 29.1 mg/kg, female; about 35.2 mg/kg), of 3.96 mg/body as GTN in rats (male; about 26.0 mg/kg, female; about 28.9 mg/kg) and of 480 mg/kg as GTN in rabbits. There were not toxic signs in mice and rats. The below findings were observed in rabbits treated mainly with NT-1 ointment: decreased spontaneous activity, decreased reactivity to various stimuli such as sound and touch, and behavior of binding food box. However, the rabbits recovered from those abnormal behavior in a day. Any body weight changes and any autopsy findings attributable to NT-1 tape or ointment were not observed in mice, rats and rabbits. The effects on ECG were not observed in rabbits. The GTN absorption ratio in rabbits treated with NT-1 ointment was thought to be 60-70% from GTN residual ratio. The skin irritation was not observed in rabbits treated with NT-1 tape.

Administration, Cutaneous↗

[Reproduction study of 1,1,3-trimethyl-5-phenylbiuret (ST-281): teratological study in rabbits by oral administration].

Teratogenicity of 1,1,3-trimethyl-5-phenylbiuret (ST-281), a new anti-rheumatic agent, was evaluated in rabbits. ST-281 at doses of 0, 50, 100, 200 and 400 mg/kg/day were administered orally to pregnant NZW rabbits from day 6 to day 18 of pregnancy. Body weight and food consumption at the administration and the subsequent periods were significantly decreased in 400 mg/kg/day group, and 5 dams (41.7%) affected severely were dead. No remarkable changes were investigated in findings at near-term caesarean section in any dosed group including 400 mg/kg/day. In visceral and skeletal examinations, no significant increase in incidence of abnormal fetuses were observed. This report suggests that ST-281 has no embryotoxicity or teratogenicity in rabbits.

Abnormalities, Drug-Induced↗

Comparison of acyl-oxyester and acyl-thioester lipids as substrates for bovine milk lipoprotein lipase.

The dithioester analog of dihexanoylphosphatidylcholine, rac-1,2-S,S-dihexanoyl-3-phosphocholine-1,2-dimercapto-3-propanol was synthesized and compared to the corresponding acyl-oxyester lipid as a substrate for bovine milk lipoprotein lipase. The apparent maximal reaction velocity (Vmax) for dihexanoyldithiophosphatidylcholine was considerably lower than that for dihexanoylphosphatidylcholine (0.12 vs. 5.0 mumol product released/min per mg lipoprotein lipase, respectively). The apparent Km values were 1.9 and 4.0 mM, respectively. 3-Butyrylthio-1,2-dibutyryloxypropane was also compared to tributyrylglycerol as a substrate for lipoprotein lipase; hydrolysis of the acyl-thioester bond was insignificant when compared to the corresponding oxyester derivative. Apolipoprotein C-II, the activator protein of lipoprotein lipase for long-chain fatty acyl substrates, had no effect on the hydrolysis of either the thio- or oxyester short-chain substrates. The low lipoprotein lipase activity for the thioester substrates is discussed in relation to the structure of the lipid and the active site of the enzyme.

Animals↗

Modification of apolipoprotein C-II with 1,2-cyclohexanedione and 2,3-butanedione. Role of arginine in the activation of lipoprotein lipase.

Apolipoprotein C-II, the activator protein of lipoprotein lipase, contains 78 amino acids with a single residue of arginine at position 49. Chemical modification of apolipoprotein C-II with 1,2-cyclohexanedione or 2,3-butanedione results in a loss of both the arginine residue and the ability of the protein to enhance the activity of bovine milk lipoprotein lipase toward a trioleoylglycerol substrate; removal of the modifying group restores arginine and more than 70% of the activating property of the apolipoprotein. Arginine modification of apolipoprotein C-II does not effect its lipid-binding properties as assessed by its association to sonicated vesicles of dimyristoylphosphatidylcholine. Furthermore, secondary structure associated with complex formation with dimyristoylphosphatidylcholine are nearly identical for the unmodified, 1,2-cyclohexanedione-modified or modified-reversed proteins. These results suggest that arginine-49 of apolipoprotein C-II is situated at or near an amino acid sequence domain involved in the activation of lipoprotein lipase. However, a guanidinium group is not required for lipid binding.

Animals↗

Effect of apolipoprotein C-II on the temperature dependence of lipoprotein lipase-catalyzed hydrolysis of phosphatidylcholines. A hydrophobic model for the mechanism.

The lipoprotein lipase-catalyzed hydrolysis of diacylphosphatidylcholines (PC) in mixed micelles of Triton X-100/PC was studied as a function of temperature in the presence and absence of apolipoprotein C-II (apo-C-II), the activator protein for lipoprotein lipase. Dilauroyl-, dimyristoyl-, dipalmitoyl-, and distearoyl-phosphatidylcholine (di-C12-PC, di-C14-PC, di-C16-PC, and di-C18-PC, respectively) were used as substrates. No systematic relationship between substrate fatty acyl chain length and either the rates of the activation energies for hydrolysis in the presence or absence of apo-C-II was observed. However, there was a linear relationship between fatty acyl chain length and both the logarithm of the activation factor (the ratio of enzyme activity with apo-C-II to that without apo-C-II) and the difference in activation energy in the presence and absence of apo-C-II. These relationships were not the result of an alteration in the physical form of the substrate, since a mixture of di-C14-PC and di-C16-PC gave activation factors for each PC which were the same as those obtained for each individual lipid. From the temperature dependence of the activation factor, thermodynamic functions of the apo-C-II-induced change in the reaction pathway were calculated. The free energy of activation decreased linearly with increasing chain length as the result of a linear increase in activation entropy which more than offset the unfavorable increase in activation enthalpy. We propose that the apo-C-II-mediated increase in the rate of the lipoprotein lipase-catalyzed hydrolysis of phosphatidylcholine is associated with transfer of a fatty acyl chain of the substrate or product to a more hydrophobic environment within the transition state complex.

Animals↗

Lipoprotein lipase-catalyzed hydrolysis of dimyristoylphosphatidylcholine. Effect of lipid organization and apolipoprotein C-II on enzyme activity.

The effect of phospholipid organization on the lipoprotein lipase-catalyzed hydrolysis of dimyristoylphosphatidylcholine was examined with sonicated vesicles and Triton X-100 or lysomyristoylphosphatidylcholine solubilized lipid. Triton X-100-dimyristoylphosphatidylcholine substrates were prepared at various ratios of detergent to phospholipid so as to produce lipid structures varying from bilayers to micelles. Apolipoprotein C-II, the activator protein for lipoprotein lipase, enhanced the rate of the lipoprotein lipase-catalyzed hydrolysis of dimyristoylphosphatidylcholine for each substrate tested. Although the absolute rate of lipoprotein lipase catalysis was different for each, the factor (the ratio of lipoprotein lipase activity with apolipoprotein C-II to that without the activator protein) was nearly constant, with a value of approximately 16. We conclude that the enhancement of lipoprotein lipase activity by apolipoprotein C-II is independent of the physical form of the phospholipid substrate.

Animals↗

Hydrolysis of cholesterol ester in artificial lipid mixtures by cholesterol esterase released from particulate fractions of rat arterial wall.

Acid and neutral cholesterol esterase activities in rat arterial wall were released from the lysosomal fraction and microsomal fraction respectively into the 105,000 X g supernatant fraction by treatment with Triton X-100, heparin and dextran sulfate. The percentage releases of acid cholesterol esterase by Triton X-100 (0.1%), heparin (50 micrograms/ml) and dextran sulfate (1 mg/ml) were 21%, 18% and 4%, respectively, while those of neutral cholesterol esterase were 66%, 56% and 39%, respectively. The cholesterol esterase released by dextran sulfate, especially that from the microsomal fraction, hydrolyzed cholesterol ester in artificial lipid mixtures with similar lipid compositions to those of the deposits in fatty streaks and fibrous plaques of atheromatous lesions.

Animals↗

Chain length dependence of phosphatidylcholine hydrolysis catalyzed by lipoprotein lipase. Effect of apolipoprotein C-II.

The effect of apolipoprotein C-II (apoC-II) on the bovine milk lipoprotein lipase (LpL)-catalyzed hydrolysis of a homologous series of saturated phosphatidylcholines was examined with respect to the fatty acyl chain length of the substrates. Dilauryl-, dimyristoyl-, dipalmitoyl-, and distearoylphosphatidylcholine solubilized by Triton X-100 and sonicated vesicles of dimyristoylphosphatidylcholine were used as substrates. The maximal rate of the LpL-catalyzed hydrolysis of each of these lipids was determined in the absence and presence of apoC-II. The activation factor (the ratio of enzyme activity with apoC-II to that without the activator protein) increased with increasing mol ratios of apoC-II to LpL and was maximal at a ratio of approximately 50. At all apoC-II/LpL mole ratios tested, the activation factor increased as a function of fatty acyl chain length. A quantitative relationship between fatty acyl chain length and the extent of maximal activation of LpL by apoC-II was observed: the logarithm of the activation factor is a linear function of the number of carbon atoms of a single fatty acyl chain of the substrates.

Animals↗

Effect of apolipoprotein C-II on the lipoprotein lipase-catalyzed hydrolysis of dihexanoyl- and diheptanoyl-phosphatidylcholine.

The effect of apolipoprotein C-II (apoC-II) on the lipoprotein lipase (LpL)-catalyzed hydrolysis of phospholipids was studied using purified bovine milk LpL and dihexanoyl (diC6) and diheptanoyl (diC7) phosphatidylcholine. In contrast to porcine pancreatic phospholipase A2, the LpL-catalyzed hydrolysis of these short-chain lecithins was not enhanced at substrate concentrations above the critical micelle concentration of the lipids. Furthermore, apoC-II had no effect on enzyme catalysis.

Animals↗